Compare COLD & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLD | FOLD |
|---|---|---|
| Founded | 1903 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2018 | 2007 |
| Metric | COLD | FOLD |
|---|---|---|
| Price | $12.80 | $10.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 7 |
| Target Price | $15.93 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 7.6M | 4.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,407,000.00 | $598,704,000.00 |
| Revenue This Year | N/A | $21.49 |
| Revenue Next Year | N/A | $18.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.28 |
| 52 Week Low | $10.10 | $5.51 |
| 52 Week High | $23.52 | $11.00 |
| Indicator | COLD | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 77.41 |
| Support Level | $10.51 | $9.73 |
| Resistance Level | $11.33 | $10.05 |
| Average True Range (ATR) | 0.45 | 0.36 |
| MACD | 0.32 | 0.04 |
| Stochastic Oscillator | 96.90 | 77.53 |
Americold Realty Trust Inc is the world's second-largest owner and operator of temperature-controlled warehouses behind privately held Lineage Logistics. The Atlanta, Georgia-based firm owns and operates approximately 239 temperature-controlled warehouses, spanning 1.4 billion cubic feet. In 2022, the firm derived more than 80% of its revenue from the United States but also has sizable operations in Europe, Canada, Australia, and New Zealand. Americold supplements its core business by providing supply management and transportation services to its various customers. It operates as a real estate investment trust.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.